Excessive sugar consumption is increasingly considered as a contributor to the emerging
epidemics of obesity and the associated cardiometabolic disease. Sugar is added to the diet …

Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease
worldwide. With no Food and Drug Administration approved drugs, current treatment options …

Elevated liver de novo lipogenesis contributes to non-alcoholic steatohepatitis (NASH) and
can be inhibited by targeting acetyl-CoA carboxylase (ACC). However, hypertriglyceridemia …

Background The incidence of non-alcoholic fatty liver disease (NAFLD) is rapidly increasing
worldwide parallel to the global obesity epidemic. NAFLD encompasses a range of liver …

The hepatic accumulation of excess triglycerides is a seminal event in the initiation and
progression of non-alcoholic fatty liver disease (NAFLD). Hepatic steatosis occurs when the …

Fragment-based drug discovery (FBDD) continues to evolve and make an impact in the
pharmaceutical sciences. We summarize successful fragment-to-lead studies that were …

Highlights•Molecular medicinal properties: Pharmacodynamics, physiochemical and
pharmacokinetic properties (P3-properties).•Successful innovation: Drug to drug, Drug to …

An analysis of 156 published clinical candidates from the Journal of Medicinal Chemistry
between 2018 and 2021 was conducted to identify lead generation strategies most …

Given the importance and beneficial characteristics of decorated azetidines in medicinal
chemistry, efficient strategies for their synthesis are highly sought after. Herein, we report a …

Our understanding of nonalcoholic steatohepatitis (NASH) pathophysiology continues to
advance rapidly. Given the complexity of the pathogenesis of NASH, the field has moved …